 | • レポートコード：MRC23Q35818 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、88ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のベッカー筋ジストロフィー市場について調査・分析し、世界のベッカー筋ジストロフィー市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（内科的治療、手術治療）、用途別セグメント分析（病院、診療所、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Italfarmaco Spa、Milo Biotechnology Llc、Ptc Therapeutics Inc、Reveragen Biopharma Inc、Sarepta Therapeutics Incなどが含まれています。世界のベッカー筋ジストロフィー市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、ベッカー筋ジストロフィー市場規模を推定する際に考慮しました。本レポートは、ベッカー筋ジストロフィーの世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、ベッカー筋ジストロフィーに関するビジネス上の意思決定に役立てることを目的としています。 ・ベッカー筋ジストロフィー市場の概要 - ベッカー筋ジストロフィーのタイプ別セグメント - 世界のベッカー筋ジストロフィー市場規模：タイプ別分析（内科的治療、手術治療） - ベッカー筋ジストロフィーの用途別セグメント - 世界のベッカー筋ジストロフィー市場規模：用途別分析（病院、診療所、その他） - 世界のベッカー筋ジストロフィー市場規模予測（2018年-2029年） ・ベッカー筋ジストロフィー市場の成長トレンド - ベッカー筋ジストロフィーの地域別市場規模（2018年-2029年） - ベッカー筋ジストロフィー市場ダイナミクス - ベッカー筋ジストロフィーの業界動向 - ベッカー筋ジストロフィー市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：内科的治療、手術治療 - 世界のベッカー筋ジストロフィーのタイプ別市場規模（2018年-2023年） - 世界のベッカー筋ジストロフィーのタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、診療所、その他 - 世界のベッカー筋ジストロフィーの用途別市場規模（2018年-2023年） - 世界のベッカー筋ジストロフィーの用途別市場規模（2024年-2029年） ・ベッカー筋ジストロフィーの地域別市場規模 - 北米のベッカー筋ジストロフィー市場規模（2018年-2029年） - アメリカのベッカー筋ジストロフィー市場規模（2018年-2029年） - ヨーロッパのベッカー筋ジストロフィー市場規模（2018年-2029年） - アジア太平洋のベッカー筋ジストロフィー市場規模（2018年-2029年） - 中国のベッカー筋ジストロフィー市場規模（2018年-2029年） - 日本のベッカー筋ジストロフィー市場規模（2018年-2029年） - 韓国のベッカー筋ジストロフィー市場規模（2018年-2029年） - インドのベッカー筋ジストロフィー市場規模（2018年-2029年） - オーストラリアのベッカー筋ジストロフィー市場規模（2018年-2029年） - 中南米のベッカー筋ジストロフィー市場規模（2018年-2029年） - 中東・アフリカのベッカー筋ジストロフィー市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Italfarmaco Spa、Milo Biotechnology Llc、Ptc Therapeutics Inc、Reveragen Biopharma Inc、Sarepta Therapeutics Inc ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Becker Muscular Dystropy market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Becker Muscular Dystropy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Becker Muscular Dystropy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Becker Muscular Dystropy in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Becker Muscular Dystropy include Italfarmaco Spa, Milo Biotechnology Llc, Ptc Therapeutics Inc, Reveragen Biopharma Inc and Sarepta Therapeutics Inc, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Becker Muscular Dystropy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Becker Muscular Dystropy.
The Becker Muscular Dystropy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Becker Muscular Dystropy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Becker Muscular Dystropy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Italfarmaco Spa
Milo Biotechnology Llc
Ptc Therapeutics Inc
Reveragen Biopharma Inc
Sarepta Therapeutics Inc
Segment by Type
Medical Treatement
Operation Treatment
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Becker Muscular Dystropy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Becker Muscular Dystropy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Medical Treatement
1.2.3 Operation Treatment
1.3 Market by Application
1.3.1 Global Becker Muscular Dystropy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Becker Muscular Dystropy Market Perspective (2018-2029)
2.2 Becker Muscular Dystropy Growth Trends by Region
2.2.1 Global Becker Muscular Dystropy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Becker Muscular Dystropy Historic Market Size by Region (2018-2023)
2.2.3 Becker Muscular Dystropy Forecasted Market Size by Region (2024-2029)
2.3 Becker Muscular Dystropy Market Dynamics
2.3.1 Becker Muscular Dystropy Industry Trends
2.3.2 Becker Muscular Dystropy Market Drivers
2.3.3 Becker Muscular Dystropy Market Challenges
2.3.4 Becker Muscular Dystropy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Becker Muscular Dystropy Players by Revenue
3.1.1 Global Top Becker Muscular Dystropy Players by Revenue (2018-2023)
3.1.2 Global Becker Muscular Dystropy Revenue Market Share by Players (2018-2023)
3.2 Global Becker Muscular Dystropy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Becker Muscular Dystropy Revenue
3.4 Global Becker Muscular Dystropy Market Concentration Ratio
3.4.1 Global Becker Muscular Dystropy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Becker Muscular Dystropy Revenue in 2022
3.5 Becker Muscular Dystropy Key Players Head office and Area Served
3.6 Key Players Becker Muscular Dystropy Product Solution and Service
3.7 Date of Enter into Becker Muscular Dystropy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Becker Muscular Dystropy Breakdown Data by Type
4.1 Global Becker Muscular Dystropy Historic Market Size by Type (2018-2023)
4.2 Global Becker Muscular Dystropy Forecasted Market Size by Type (2024-2029)
5 Becker Muscular Dystropy Breakdown Data by Application
5.1 Global Becker Muscular Dystropy Historic Market Size by Application (2018-2023)
5.2 Global Becker Muscular Dystropy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Becker Muscular Dystropy Market Size (2018-2029)
6.2 North America Becker Muscular Dystropy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Becker Muscular Dystropy Market Size by Country (2018-2023)
6.4 North America Becker Muscular Dystropy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Becker Muscular Dystropy Market Size (2018-2029)
7.2 Europe Becker Muscular Dystropy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Becker Muscular Dystropy Market Size by Country (2018-2023)
7.4 Europe Becker Muscular Dystropy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Becker Muscular Dystropy Market Size (2018-2029)
8.2 Asia-Pacific Becker Muscular Dystropy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Becker Muscular Dystropy Market Size by Region (2018-2023)
8.4 Asia-Pacific Becker Muscular Dystropy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Becker Muscular Dystropy Market Size (2018-2029)
9.2 Latin America Becker Muscular Dystropy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Becker Muscular Dystropy Market Size by Country (2018-2023)
9.4 Latin America Becker Muscular Dystropy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Becker Muscular Dystropy Market Size (2018-2029)
10.2 Middle East & Africa Becker Muscular Dystropy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Becker Muscular Dystropy Market Size by Country (2018-2023)
10.4 Middle East & Africa Becker Muscular Dystropy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Italfarmaco Spa
11.1.1 Italfarmaco Spa Company Detail
11.1.2 Italfarmaco Spa Business Overview
11.1.3 Italfarmaco Spa Becker Muscular Dystropy Introduction
11.1.4 Italfarmaco Spa Revenue in Becker Muscular Dystropy Business (2018-2023)
11.1.5 Italfarmaco Spa Recent Development
11.2 Milo Biotechnology Llc
11.2.1 Milo Biotechnology Llc Company Detail
11.2.2 Milo Biotechnology Llc Business Overview
11.2.3 Milo Biotechnology Llc Becker Muscular Dystropy Introduction
11.2.4 Milo Biotechnology Llc Revenue in Becker Muscular Dystropy Business (2018-2023)
11.2.5 Milo Biotechnology Llc Recent Development
11.3 Ptc Therapeutics Inc
11.3.1 Ptc Therapeutics Inc Company Detail
11.3.2 Ptc Therapeutics Inc Business Overview
11.3.3 Ptc Therapeutics Inc Becker Muscular Dystropy Introduction
11.3.4 Ptc Therapeutics Inc Revenue in Becker Muscular Dystropy Business (2018-2023)
11.3.5 Ptc Therapeutics Inc Recent Development
11.4 Reveragen Biopharma Inc
11.4.1 Reveragen Biopharma Inc Company Detail
11.4.2 Reveragen Biopharma Inc Business Overview
11.4.3 Reveragen Biopharma Inc Becker Muscular Dystropy Introduction
11.4.4 Reveragen Biopharma Inc Revenue in Becker Muscular Dystropy Business (2018-2023)
11.4.5 Reveragen Biopharma Inc Recent Development
11.5 Sarepta Therapeutics Inc
11.5.1 Sarepta Therapeutics Inc Company Detail
11.5.2 Sarepta Therapeutics Inc Business Overview
11.5.3 Sarepta Therapeutics Inc Becker Muscular Dystropy Introduction
11.5.4 Sarepta Therapeutics Inc Revenue in Becker Muscular Dystropy Business (2018-2023)
11.5.5 Sarepta Therapeutics Inc Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
